相关实验视频

Updated: Jun 25, 2025

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

陶鲁二氧化醇酸可以缓解由COL4A3突变引起的损伤

Shuwen Yu¹, Xiangchen Gu², Qimin Zheng¹

¹Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Institute of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Kidney international

|May 23, 2024

概括

阿尔波特综合征是由COL4A3/A4/A5突变引起的. 陶鲁尔苏氧胆酸 (TUDCA) 降低了内分泌网膜的压力和炎症,在一个新的阿尔波特综合征小鼠模型中改善了功能.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

COL4A3/A4/A5基因的突变是阿尔波特综合征和其他遗传性脏疾病的主要原因.
驱动阿尔波特综合征发病的精确机制和有效的治疗策略在很大程度上仍未确定.

研究的目的:

通过使用新型转基因小鼠模型,研究阿尔波特综合征的分子病变发生.
评估tauroursodeoxycholic acid (TUDCA) 在缓解与阿尔波特综合征相关的损伤方面的治疗潜力.

主要方法:

产生一种具有特定Col4a3突变 (p.G799R) 的转基因小鼠模型.
通过RNA测序分析原蛋白IV异构三聚合物水平,内质网膜 (ER) 压力标志物和炎症途径.
在体内评估TUDCA治疗对ER压力,IV原分泌,通路激活和功能的影响.

主要成果:

引入的Col4a3突变导致降低了IV原α3α4α5异构分泌物分泌,并诱导了持续的ER压力.
RNA-seq确定了MyD88/p38 MAPK通路对于炎症和亡至关重要.
TUDCA治疗改善了ER压力,增强了α3链分泌,抑制了MyD88/p38 MAPK通路,并改善了功能.

结论:

该研究阐明了阿尔波特综合征的关键病原机制,特别是球损伤,涉及ER压力和MyD88/p38 MAPK通路.
在阿尔波特综合征的早期临床干预中,TUDCA通过准ER压力和炎症,展示了治疗前景.

关键词:

阿尔波特综合征是什么意思灭症 (apoptosis) 是一种死亡的过程.细胞内膜网膜的内oplasmic网膜.纤维化纤维化这是一种炎症炎症炎症炎症.

更多相关视频

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...